Issue of Equity
THIS ANNOUNCEMENT (THE "ANNOUNCEMENT")
AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR
RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY
OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA,
CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER
JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION
WOULD BE UNLAWFUL.
THIS ANNOUNCEMENT CONTAINS INSIDE
INFORMATION FOR THE PURPOSES OF THE MARKET ABUSE REGULATION
(596/2014/EU) ("MAR"). IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN
MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED IN
THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME
AWARE OF SUCH INSIDE INFORMATION, AS PERMITTED BY MAR. UPON THE
PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW
CONSIDERED TO BE IN THE PUBLIC DOMAIN AND SUCH PERSONS SHALL
THEREFORE CEASE TO BE IN POSSESSION OF INSIDE
INFORMATION.
DXS INTERNATIONAL PLC
Issue of Equity
DXS International plc ("DXS", the "Company"),
the digital clinical decision support company, is pleased
to confirm that, following its announcement on 19th
February 2020, the Company has today completed
the placing and subscription of ordinary shares to raise just
over GBP 1 million. The Company confirms that a total of 12,675,000
new ordinary shares were issued and admitted to trading today and
that following the fundraising, the Company has a total of
48,256,416 ordinary shares in issue.
David Immelman, CEO of DXS International plc
commented: "I'm delighted to have received this supportive funding
at a high growth phase in the Company's development as DXS moves
into scale up and further commercialisation."
The Directors of DXS International plc accept
responsibility for this announcement
Contacts:
David
Immelman (Chief Executive)DXS International
plc |
01252 719800david@dxs-systems.com |
https://www.dxs-systems.co.uk |
|
Corporate
Advisor |
|
City &
Merchant Limited David
Papworth |
020 7101 7676 |
Corporate
Broker and sole broker to the
Placing |
|
Hybridan
LLPClaire Louise Noyce |
020 3764 2341 |
Notes to Editors
About DXS:
DXS International plc presents up to date
treatment guidelines and recommendations, from Clinical
Commissioning Groups and other trusted NHS sources, to doctors,
nurses and pharmacists in their workflow and during the patient
consultation. This effective clinical decision support ultimately
translates to improved healthcare outcomes delivered more cost
effectively and which should significantly contribute towards the
NHS achieving its projected efficiency savings.
DXS (AQSE:DXSP)
Historical Stock Chart
From Jun 2024 to Jul 2024
DXS (AQSE:DXSP)
Historical Stock Chart
From Jul 2023 to Jul 2024